Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 19 | 2025 | 1020 | 1.790 |
Why?
|
| Heart Transplantation | 11 | 2025 | 800 | 1.510 |
Why?
|
| Heart Failure | 18 | 2024 | 2332 | 1.320 |
Why?
|
| Heart Ventricles | 5 | 2025 | 749 | 0.460 |
Why?
|
| Thrombectomy | 1 | 2016 | 117 | 0.450 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 182 | 0.420 |
Why?
|
| Hemostatics | 3 | 2021 | 58 | 0.410 |
Why?
|
| Cardiac Catheterization | 2 | 2025 | 630 | 0.400 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 2 | 2026 | 140 | 0.390 |
Why?
|
| Pulmonary Artery | 1 | 2016 | 434 | 0.380 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2021 | 77 | 0.320 |
Why?
|
| Retrospective Studies | 21 | 2025 | 17753 | 0.270 |
Why?
|
| Endovascular Procedures | 1 | 2016 | 802 | 0.270 |
Why?
|
| Hemostasis, Surgical | 2 | 2019 | 34 | 0.260 |
Why?
|
| Macrophages, Alveolar | 1 | 2026 | 52 | 0.240 |
Why?
|
| Treatment Outcome | 16 | 2025 | 12936 | 0.230 |
Why?
|
| Ventricular Pressure | 1 | 2025 | 34 | 0.230 |
Why?
|
| Pulmonary Fibrosis | 1 | 2026 | 112 | 0.220 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2026 | 127 | 0.220 |
Why?
|
| Inflammasomes | 1 | 2026 | 154 | 0.220 |
Why?
|
| Weaning | 2 | 2021 | 52 | 0.210 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2022 | 682 | 0.210 |
Why?
|
| Hospitals | 2 | 2024 | 435 | 0.200 |
Why?
|
| Cholesterol | 1 | 2026 | 539 | 0.200 |
Why?
|
| Humans | 39 | 2026 | 131163 | 0.200 |
Why?
|
| Ice | 1 | 2023 | 5 | 0.190 |
Why?
|
| Echocardiography | 5 | 2025 | 1125 | 0.190 |
Why?
|
| Stroke | 3 | 2023 | 1061 | 0.190 |
Why?
|
| Postoperative Complications | 3 | 2021 | 3147 | 0.190 |
Why?
|
| Stem Cell Transplantation | 2 | 2019 | 227 | 0.180 |
Why?
|
| Macrophages | 1 | 2026 | 667 | 0.180 |
Why?
|
| Equipment Failure | 3 | 2021 | 122 | 0.180 |
Why?
|
| Vasoplegia | 1 | 2022 | 22 | 0.170 |
Why?
|
| Lung | 3 | 2026 | 1535 | 0.170 |
Why?
|
| Heart Defects, Congenital | 2 | 2025 | 1889 | 0.170 |
Why?
|
| Sarcopenia | 1 | 2022 | 56 | 0.170 |
Why?
|
| Ventricular Function | 1 | 2021 | 81 | 0.170 |
Why?
|
| Thrombin | 1 | 2021 | 57 | 0.160 |
Why?
|
| Pulmonary Valve | 1 | 2021 | 83 | 0.160 |
Why?
|
| Counterpulsation | 1 | 2020 | 2 | 0.160 |
Why?
|
| Ventricular Function, Right | 1 | 2021 | 126 | 0.160 |
Why?
|
| Adaptation, Physiological | 1 | 2021 | 258 | 0.150 |
Why?
|
| Middle Aged | 17 | 2025 | 28601 | 0.150 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2020 | 42 | 0.150 |
Why?
|
| Kidney Transplantation | 1 | 2025 | 558 | 0.150 |
Why?
|
| Blood Pressure Determination | 1 | 2020 | 118 | 0.150 |
Why?
|
| Exercise Tolerance | 1 | 2020 | 91 | 0.150 |
Why?
|
| Cardiomyopathies | 2 | 2019 | 514 | 0.150 |
Why?
|
| Ventricular Function, Left | 4 | 2025 | 549 | 0.150 |
Why?
|
| Postoperative Hemorrhage | 1 | 2019 | 83 | 0.140 |
Why?
|
| Prosthesis Implantation | 2 | 2021 | 152 | 0.140 |
Why?
|
| Catheterization, Peripheral | 1 | 2020 | 118 | 0.140 |
Why?
|
| Amyloidosis | 1 | 2019 | 70 | 0.140 |
Why?
|
| Survival Rate | 5 | 2021 | 2114 | 0.140 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 303 | 0.140 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2021 | 228 | 0.140 |
Why?
|
| Shock, Cardiogenic | 1 | 2020 | 176 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 146 | 0.140 |
Why?
|
| Patient Care Team | 2 | 2020 | 562 | 0.130 |
Why?
|
| Perioperative Care | 1 | 2020 | 217 | 0.130 |
Why?
|
| Graft Rejection | 1 | 2021 | 552 | 0.130 |
Why?
|
| Stroke Volume | 1 | 2020 | 541 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 209 | 0.130 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 225 | 0.130 |
Why?
|
| Heart Rate | 1 | 2020 | 577 | 0.130 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2021 | 425 | 0.130 |
Why?
|
| Cardiac Catheters | 1 | 2016 | 11 | 0.120 |
Why?
|
| Female | 21 | 2026 | 70963 | 0.120 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 2304 | 0.120 |
Why?
|
| Patient-Specific Modeling | 1 | 2016 | 12 | 0.120 |
Why?
|
| Scleroderma, Systemic | 1 | 2018 | 118 | 0.120 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 53 | 0.120 |
Why?
|
| Patient Selection | 2 | 2025 | 729 | 0.120 |
Why?
|
| Adult | 14 | 2025 | 31282 | 0.120 |
Why?
|
| Male | 20 | 2026 | 64957 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2025 | 1147 | 0.120 |
Why?
|
| Models, Anatomic | 1 | 2016 | 105 | 0.110 |
Why?
|
| Printing, Three-Dimensional | 1 | 2016 | 88 | 0.110 |
Why?
|
| Coronary Artery Bypass | 1 | 2019 | 515 | 0.110 |
Why?
|
| Models, Cardiovascular | 1 | 2016 | 165 | 0.110 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 205 | 0.110 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 216 | 0.110 |
Why?
|
| Equipment Contamination | 1 | 2014 | 38 | 0.110 |
Why?
|
| Starch | 1 | 2014 | 26 | 0.110 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 371 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2022 | 5196 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2018 | 398 | 0.100 |
Why?
|
| Withholding Treatment | 1 | 2014 | 76 | 0.100 |
Why?
|
| Heart, Artificial | 1 | 2014 | 46 | 0.100 |
Why?
|
| Device Removal | 1 | 2015 | 225 | 0.100 |
Why?
|
| Blood Loss, Surgical | 1 | 2014 | 168 | 0.100 |
Why?
|
| Quality of Life | 2 | 2020 | 2082 | 0.100 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2014 | 177 | 0.100 |
Why?
|
| Lung Transplantation | 1 | 2018 | 363 | 0.100 |
Why?
|
| Risk Factors | 7 | 2025 | 11074 | 0.090 |
Why?
|
| Elective Surgical Procedures | 1 | 2013 | 162 | 0.090 |
Why?
|
| Terminal Care | 1 | 2014 | 119 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 887 | 0.090 |
Why?
|
| Aged | 9 | 2025 | 21025 | 0.090 |
Why?
|
| Recovery of Function | 3 | 2020 | 449 | 0.090 |
Why?
|
| Consensus | 1 | 2014 | 512 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 1410 | 0.090 |
Why?
|
| Bacteremia | 1 | 2014 | 446 | 0.080 |
Why?
|
| Obesity | 1 | 2021 | 2426 | 0.080 |
Why?
|
| Critical Illness | 1 | 2014 | 630 | 0.070 |
Why?
|
| Thrombosis | 1 | 2014 | 499 | 0.070 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2015 | 1168 | 0.070 |
Why?
|
| Reoperation | 2 | 2021 | 818 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2025 | 3711 | 0.060 |
Why?
|
| Cyclin A | 1 | 2007 | 16 | 0.060 |
Why?
|
| Myocardial Ischemia | 2 | 2007 | 307 | 0.060 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 38 | 0.060 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2026 | 152 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 1216 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2006 | 67 | 0.060 |
Why?
|
| Prognosis | 3 | 2021 | 4886 | 0.060 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2025 | 45 | 0.060 |
Why?
|
| Heart-Lung Transplantation | 1 | 2025 | 16 | 0.060 |
Why?
|
| Equipment Design | 2 | 2019 | 512 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 1 | 2006 | 197 | 0.050 |
Why?
|
| Regeneration | 1 | 2007 | 230 | 0.050 |
Why?
|
| Stromal Cells | 1 | 2006 | 316 | 0.050 |
Why?
|
| Aortic Valve | 2 | 2020 | 455 | 0.050 |
Why?
|
| Prosthesis Design | 2 | 2020 | 643 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2025 | 263 | 0.050 |
Why?
|
| Young Adult | 4 | 2021 | 10103 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2025 | 365 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 468 | 0.050 |
Why?
|
| Myofibroblasts | 1 | 2023 | 64 | 0.050 |
Why?
|
| Cannula | 1 | 2023 | 32 | 0.050 |
Why?
|
| Thorax | 1 | 2023 | 63 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2025 | 314 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2007 | 710 | 0.050 |
Why?
|
| Organ Preservation | 1 | 2023 | 62 | 0.040 |
Why?
|
| Stem Cells | 2 | 2023 | 702 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2023 | 780 | 0.040 |
Why?
|
| Axilla | 1 | 2021 | 43 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2007 | 668 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2025 | 810 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 3061 | 0.040 |
Why?
|
| Powders | 1 | 2021 | 25 | 0.040 |
Why?
|
| Ventricular Fibrillation | 1 | 2021 | 51 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2025 | 499 | 0.040 |
Why?
|
| Time Factors | 2 | 2021 | 6196 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 331 | 0.040 |
Why?
|
| Allografts | 1 | 2021 | 220 | 0.040 |
Why?
|
| Video Recording | 1 | 2021 | 193 | 0.040 |
Why?
|
| Axillary Artery | 1 | 2020 | 31 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2021 | 235 | 0.040 |
Why?
|
| Cardiologists | 1 | 2020 | 26 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2020 | 48 | 0.040 |
Why?
|
| Anesthesiologists | 1 | 2020 | 43 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 239 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2022 | 361 | 0.040 |
Why?
|
| Ultrasonography, Doppler | 1 | 2020 | 187 | 0.040 |
Why?
|
| Monitoring, Intraoperative | 1 | 2020 | 127 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 333 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2020 | 195 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2020 | 124 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2021 | 358 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2026 | 4697 | 0.040 |
Why?
|
| Postpartum Period | 1 | 2021 | 245 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2023 | 849 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2019 | 254 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2026 | 3819 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 824 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2026 | 4738 | 0.030 |
Why?
|
| Heart | 1 | 2021 | 650 | 0.030 |
Why?
|
| Rats, Inbred Lew | 2 | 2007 | 59 | 0.030 |
Why?
|
| Global Health | 1 | 2021 | 626 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1483 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 6797 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2021 | 1717 | 0.030 |
Why?
|
| Critical Care | 1 | 2021 | 686 | 0.030 |
Why?
|
| Surgeons | 1 | 2020 | 289 | 0.030 |
Why?
|
| United States | 2 | 2021 | 12072 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2020 | 1345 | 0.030 |
Why?
|
| Animals | 4 | 2026 | 33912 | 0.030 |
Why?
|
| Incidence | 1 | 2022 | 3360 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2015 | 146 | 0.030 |
Why?
|
| Texas | 1 | 2022 | 3686 | 0.030 |
Why?
|
| Mortality | 1 | 2014 | 264 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2014 | 417 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 3359 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 613 | 0.020 |
Why?
|
| Mitral Valve | 1 | 2014 | 247 | 0.020 |
Why?
|
| Rats | 2 | 2007 | 3370 | 0.020 |
Why?
|
| Registries | 1 | 2017 | 1634 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 6459 | 0.020 |
Why?
|
| Mice | 1 | 2026 | 18301 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1797 | 0.020 |
Why?
|
| Adolescent | 2 | 2020 | 20987 | 0.020 |
Why?
|
| Pregnancy | 1 | 2021 | 7512 | 0.020 |
Why?
|
| Cyclin A2 | 1 | 2007 | 4 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2007 | 36 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2007 | 46 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2006 | 36 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2006 | 27 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 119 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 191 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2007 | 579 | 0.010 |
Why?
|
| Cell Survival | 1 | 2006 | 826 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2007 | 892 | 0.010 |
Why?
|
| Cell Movement | 1 | 2006 | 876 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2007 | 999 | 0.010 |
Why?
|
| Apoptosis | 1 | 2006 | 1827 | 0.010 |
Why?
|